Recombinant vaccine viruses expressing IL-15 and methods using the same

US8663622B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Liyanage Parakrama Perera · Bethesda, US
• Thomas Waldmann · Silver Spring, US
• Sang-Kon Oh · Baltimore, US
• Jay A. Berzofsky · Bethesda, US

Key dates

• Filing date: Dec 15, 2003
• Grant date: Mar 4, 2014
• Expiry date: Nov 17, 2024

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.